Zymeworks Statistics
Share Statistics
Zymeworks has 68.88M shares outstanding. The number of shares has increased by 1.49% in one year.
| Shares Outstanding | 68.88M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.48% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 66.65M |
| Failed to Deliver (FTD) Shares | 1.89K |
| FTD / Avg. Volume | 0.36% |
Short Selling Information
The latest short interest is 4.70M, so 6.82% of the outstanding shares have been sold short.
| Short Interest | 4.70M |
| Short % of Shares Out | 6.82% |
| Short % of Float | 7.01% |
| Short Ratio (days to cover) | 10.43 |
Valuation Ratios
The PE ratio is -6.03 and the forward PE ratio is -10.34.
| PE Ratio | -6.03 |
| Forward PE | -10.34 |
| PS Ratio | 9.41 |
| Forward PS | 7.3 |
| PB Ratio | 1.54 |
| P/FCF Ratio | -5.85 |
| PEG Ratio | n/a |
Enterprise Valuation
Zymeworks Inc. has an Enterprise Value (EV) of 584.65M.
| EV / Earnings | -4.93 |
| EV / Sales | 7.69 |
| EV / EBITDA | -4.5 |
| EV / EBIT | -4.23 |
| EV / FCF | -4.78 |
Financial Position
The company has a current ratio of 7.41, with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.41 |
| Quick Ratio | 7.41 |
| Debt / Equity | 0.06 |
| Total Debt / Capitalization | 5.27 |
| Cash Flow / Debt | -4.58 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.26% and return on capital (ROIC) is -27.95%.
| Return on Equity (ROE) | -0.26% |
| Return on Assets (ROA) | -0.2% |
| Return on Capital (ROIC) | -27.95% |
| Revenue Per Employee | 258.54K |
| Profits Per Employee | -403.65K |
| Employee Count | 294 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -568.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 38.68% in the last 52 weeks. The beta is 1.16, so Zymeworks 's price volatility has been higher than the market average.
| Beta | 1.16 |
| 52-Week Price Change | 38.68% |
| 50-Day Moving Average | 14.07 |
| 200-Day Moving Average | 11.1 |
| Relative Strength Index (RSI) | 34.34 |
| Average Volume (20 Days) | 527.75K |
Income Statement
In the last 12 months, Zymeworks had revenue of $76.01M and earned -$118.67M in profits. Earnings per share was $-1.72.
| Revenue | 76.01M |
| Gross Profit | -66.98M |
| Operating Income | -138.05M |
| Net Income | -118.67M |
| EBITDA | -129.96M |
| EBIT | -138.05M |
| Earnings Per Share (EPS) | -1.72 |
Balance Sheet
The company has $157.56M in cash and $26.72M in debt, giving a net cash position of $130.84M.
| Cash & Cash Equivalents | 157.56M |
| Total Debt | 26.72M |
| Net Cash | 130.84M |
| Retained Earnings | -677.44M |
| Total Assets | 487.15M |
| Working Capital | -83.57B |
Cash Flow
In the last 12 months, operating cash flow was -$118.30M and capital expenditures -$4.08M, giving a free cash flow of -$122.38M.
| Operating Cash Flow | -118.30M |
| Capital Expenditures | -4.08M |
| Free Cash Flow | -122.38M |
| FCF Per Share | -1.78 |
Margins
Gross margin is -88.11%, with operating and profit margins of -181.62% and -156.13%.
| Gross Margin | -88.11% |
| Operating Margin | -181.62% |
| Pretax Margin | -156.87% |
| Profit Margin | -156.13% |
| EBITDA Margin | -170.97% |
| EBIT Margin | -181.62% |
| FCF Margin | -161% |
Dividends & Yields
ZYME does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -13.63% |
| FCF Yield | -14.08% |
Analyst Forecast
The average price target for ZYME is $18, which is 42.6% higher than the current price. The consensus rating is "Hold".
| Price Target | $18 |
| Price Target Difference | 42.6% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -204.37 |
| Piotroski F-Score | 2 |